Skip to main content

ETHNOS_APP

Home • Search • Journals • List 0

Covid-19 vaccination

Challenges in the pediatric population

Bibliographic Data

ID22091455
AuthorsAlice Azoicăi (Grigore T. Popa University of Medicine and Pharmacy), Alice Nicoleta Azoicai, Ingrith Miron (0000-0002-9825-6711, Grigore T. Popa University of Medicine and Pharmacy), Ancuța Lupu (0000-0001-8147-3632, Grigore T. Popa University of Medicine and Pharmacy, corresponding author), Monica Mihaela Alexoae, Monica Alexoae (Grigore T. Popa University of Medicine and Pharmacy), Iuliana Magdalena Stârcea (0000-0002-3937-7425, Grigore T. Popa University of Medicine and Pharmacy), Mirabela Alecsa (0000-0003-3074-4310, Grigore T. Popa University of Medicine and Pharmacy), Vasile Valeriu Lupu (0000-0003-2640-8795, Grigore T. Popa University of Medicine and Pharmacy, corresponding author), Ciprian Danielescu (0000-0002-1639-2921, Grigore T. Popa University of Medicine and Pharmacy), Alin Horatiu Nedelcu (0000-0002-0024-0237, Grigore T. Popa University of Medicine and Pharmacy), Delia Lidia Salaru (Grigore T. Popa University of Medicine and Pharmacy), Felicia Dragan (University of Oradea), Ileana Ioniuc (0000-0003-3992-6751, Grigore T. Popa University of Medicine and Pharmacy)
Year2025
Volume12
Pages1390951-1390951
Publication date2025-01-29
Open AccessYes
TypeARTICLE
VenueFrontiers in Public Health (JOURNAL)
Journal identifiersISSN: 2296-2565 • E-ISSN: 2296-2565
PublisherFrontiers Media SA (PUBLISHER • CH)
DOI10.3389/fpubh.2024.1390951
PMID39944570
OpenAlexW4406935876
LanguageEN
References cited59

Vaccination is considered to be one of the most effective means of protecting individuals and populations from the risks associated with exposure to various pathogens. The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), affected people of all ages worldwide. In response, several pharmaceutical companies rapidly leveraged their resources to develop vaccines within a very short period of time, leading to the introduction of new, improved, and combination vaccines for community-wide immunization. This review aims to provide a summary of the available literature on the efficacy and safety of COVID-19 vaccines in the pediatric population ranging from 0 to 18 years. An analysis of recent published studies reveals that the majority of clinical trials have reported a sustained immune response following COVID-19 vaccination in children across various age groups worldwide. The majority of the authors highlighted the effectiveness and safety of immunization schedules in children and adolescents. The population-level efficacy of this vaccination remains to be determined, provided that the benefits outweigh the potential risks. Long-term side effects must still be monitored to enable the development of safer and more effective vaccines for future pandemics

Clinical trial · Disease · Environmental health · Immune system · Immunization · Intensive care medicine · Pandemic · Population · Vaccination · Medicine · SARS-CoV-2 and COVID-19 Research · Vaccine Coverage and Hesitancy · Viral gastroenteritis research and epidemiology · Immunology

  • Voluntary Covid-19 vaccination of children

    Open Access•Margherita Brusa, Yechiel Michael Barilan•Journal of Medical Ethics•2021

Highly citedNo

Tools

Open DOIOpen Access
Ethnos_APP • Open Source Project • MIT License • Frontend v2.0.0 • Privacy and Cookies • API Documentation: api.ethnos.app/docs • API Source Code: GitHub • DOI: 10.5281/zenodo.17049435 • Frontend Source Code: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae